{
  "ticker": "OSL",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02967805",
  "id": "02967805",
  "pages": 6,
  "price_sensitive": false,
  "date": "20250709",
  "time": "1348",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250709/pdf/06lmyw391hd9t2.pdf",
  "summary": "### Capital Raising Announcement Summary:  \n- **Structure**: Placement  \n- **Securities Issued**:  \n  - **Ordinary Shares (OSL)**: 17,271 shares at **AUD 1.158/share**  \n  - **Attaching Options**: 17,271 options (new class, expiry 31-Jul-2027, exercise price **AUD 1.20**)  \n- **Purpose**: Funds for clinical trials, administration, and working capital.  \n- **Issue Date**: 8-Aug-2025  \n- **Shareholder Approval**: Obtained at EGM on 8-Jul-2025.  \n- **Key Condition**: Issuance to director Dr. Gabriel Liberatore under SPP terms.  \n\n*(No underwriting, lead manager, or escarrangements noted.)*",
  "usage": {
    "prompt_tokens": 2175,
    "completion_tokens": 171,
    "total_tokens": 2346,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-09T06:22:48.015534"
}